Despite significant advances in its detection, understanding and management, atrial
fibrillation (AF) remains a highly prevalent cardiac arrhythmia with a major impact on …

After multiple drugs were removed from the market secondary to drug‐induced torsade de
pointes (TdP) risk, the International Council for Harmonisation (ICH) released guidelines in …

Human-based computational modelling and simulation are powerful tools to accelerate the
mechanistic understanding of cardiac patho-physiology, and to develop and evaluate …

In response to a surge of deaths from synthetic opioid overdoses, there have been
increased efforts to distribute naloxone products in community settings. Prior research has …

Defining an appropriate and efficient assessment of drug‐induced corrected QT interval
(QTc) prolongation (a surrogate marker of torsades de pointes arrhythmia) remains a …

Patient-specific cardiac models are now being used to guide therapies. The increased use
of patient-specific cardiac simulations in clinical care will give rise to the development of …

Cardiac arrhythmias are a major cause of death and disability. A large number of
experimental cell and animal models have been developed to study arrhythmogenic …

High-throughput in vitro drug assays have been impacted by recent advances in human
induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) technology and by contact …

At present, the QT interval on the electrocardiographic (ECG) waveform is the most common
metric for assessing an individual's susceptibility to ventricular arrhythmias, with a long QT …

The US Food and Drug Administration (FDA) Division of Applied Regulatory Science
(DARS) moves new science into the drug review process and addresses emergent …